429 related articles for article (PubMed ID: 34628896)
21. Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease.
Zhu SH; Zheng KI; Hu DS; Gao F; Rios RS; Li G; Li YY; Byrne CD; Targher G; Chen YP; Zheng MH
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):430-435. PubMed ID: 32398489
[TBL] [Abstract][Full Text] [Related]
22. Accuracy of Two-Dimensional Shear Wave Elastography and Attenuation Imaging for Evaluation of Patients With Nonalcoholic Steatohepatitis.
Lee DH; Cho EJ; Bae JS; Lee JY; Yu SJ; Kim H; Lee KB; Han JK; Choi BI
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):797-805.e7. PubMed ID: 32450363
[TBL] [Abstract][Full Text] [Related]
23. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Marra F; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Barbara M; Le-Bail B; Arena U; Craxì A; de Ledinghen V
Hepatology; 2017 Apr; 65(4):1145-1155. PubMed ID: 27639088
[TBL] [Abstract][Full Text] [Related]
24. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
[TBL] [Abstract][Full Text] [Related]
25. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
[TBL] [Abstract][Full Text] [Related]
26. Prediction of Liver-Related Events With a Combination of Liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease.
Hayashi H; Kamada Y; Fujii H; Takahashi H; Oeda S; Iwaki M; Kawaguchi T; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Ultrasound Med Biol; 2023 Jul; 49(7):1658-1664. PubMed ID: 37120329
[TBL] [Abstract][Full Text] [Related]
27. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease.
Lee HW; Park SY; Kim SU; Jang JY; Park H; Kim JK; Lee CK; Chon YE; Han KH
PLoS One; 2016; 11(6):e0157358. PubMed ID: 27284700
[TBL] [Abstract][Full Text] [Related]
28. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
29. The Role of Multiparametric US of the Liver for the Evaluation of Nonalcoholic Steatohepatitis.
Sugimoto K; Moriyasu F; Oshiro H; Takeuchi H; Abe M; Yoshimasu Y; Kasai Y; Sakamaki K; Hara T; Itoi T
Radiology; 2020 Sep; 296(3):532-540. PubMed ID: 32573385
[TBL] [Abstract][Full Text] [Related]
30. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience.
Baumeler S; Jochum W; Neuweiler J; Bergamin I; Semela D
Swiss Med Wkly; 2019 Apr; 149():w20077. PubMed ID: 31026041
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of Controlled Attenuation Parameter and Liver Stiffness Measurement for the Identification of Extended-criteria Donors and Risk-assessment in Liver Transplantation.
Duarte-Rojo A; Heimbach JK; Borja-Cacho D; Barone GW; Shaheen MF; Lamps LW; Graham RP; Tan EK; Concepcion W; Kim WR
Transplantation; 2022 Feb; 106(2):318-327. PubMed ID: 33675319
[TBL] [Abstract][Full Text] [Related]
32. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients.
Siddiqui MS; Idowu MO; Stromberg K; Sima A; Lee E; Patel S; Ghaus S; Driscoll C; Sterling RK; John B; Bhati CS
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):367-374. PubMed ID: 32272251
[TBL] [Abstract][Full Text] [Related]
34. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
35. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan.
Roulot D; Roudot-Thoraval F; NKontchou G; Kouacou N; Costes JL; Elourimi G; Le Clesiau H; Ziol M; Beaugrand M
Liver Int; 2017 Dec; 37(12):1897-1906. PubMed ID: 28556413
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.
Cardoso AC; Beaugrand M; de Ledinghen V; Douvin C; Poupon R; Trinchet JC; Ziol M; Bedossa P; Marcellin P
Ann Hepatol; 2015; 14(6):826-36. PubMed ID: 26436354
[TBL] [Abstract][Full Text] [Related]
38. Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes.
Nobarani S; Alaei-Shahmiri F; Aghili R; Malek M; Poustchi H; Lahouti M; Khamseh ME
Dig Dis Sci; 2022 Apr; 67(4):1389-1398. PubMed ID: 33788095
[TBL] [Abstract][Full Text] [Related]
39. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
40. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]